Global Genital Herpes Pipeline Landscape Report 2021: Therapeutic Assessment by Product Type, Stage, Route of Administration, and Molecule Type – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Genital Herpes – Pipeline Insight, 2021” clinical trials has been added to ResearchAndMarkets.com’s offering.

This Genital herpes – Pipeline Insight, 2021 provides comprehensive insights about 20+ companies and 20+ pipeline drugs in Genital herpes pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Genital herpes R&D. The therapies under development are focused on novel approaches to treat/improve Genital herpes.

Genital herpes Emerging Drugs Chapters

This segment of the Genital herpes report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Genital herpes Emerging Drugs

Pritelivir (AIC316): AiCuris

Pritelivir is a new small molecule, a helicase-primase inhibitor with a novel mode of action. In a phase 2 study conducted earlier for suppressive treatment, oral pritelivir showed to significantly improve the suppression of viral shedding compared to the current standard of care for genital HSV-2 infections, the nucleoside analog valacyclovir. Currently, it is in phase III stage of development to treat genital herpes.

Major Players in Genital herpes

There are approx. 20+ key companies which are developing the therapies for Genital herpes. The companies which have their Genital herpes drug candidates in the most advanced stage, i.e. phase III include, AiCuris.

Genital herpes: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Genital herpes therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Genital herpes drugs.

Key Questions Answered

• How many companies are developing Genital herpes drugs?
• How many Genital herpes drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Genital herpes?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Genital herpes therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Genital herpes and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• United Biopharma
• AiCuris
• Sanofi
• Rational Vaccines
• BlueWillow Biologics
• Heidelberg ImmunoTherapeutics
• EXCELL BIOTECH
• AlphaVax, Inc.
• NANOVIRICIDES, INC.
• Vaccibody AS
• Vaxart, Inc.
• Beech Tree Labs
• Rational Vaccines
• Auro Vaccines
• Redbiotec AG

Key Products

• UB-621
• Pritelivir (AIC316)
• HSV 2 Vaccines
• RVx-201
• NE HSV-2 Vaccine
• HDIT 101
• X-Vax Technology
• EXD-12
• BTL-TML
• RVx-201 HSV-2
• GeneVaxT prime/VesiculoVaxT

For more information about this clinical trials report visit https://www.researchandmarkets.com/r/9pdltq

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900